Klotho: The Longevity Protein Researchers Are Watching
Klotho is an aging-suppressor protein that declines with age. Learn what the science says about klotho, cognition, and longevity biomarkers to track.
Klotho: The Longevity Protein Researchers Are Watching **Klotho** is one of the most closely watched proteins in aging science, and for good reason. First identified in 1997 through mice that aged prematurely when the gene was disabled, klotho has since been linked to kidney health, brain function, the FGF23 signaling axis, and lifespan itself. Circulating klotho levels decline steadily as we get older, and a growing body of research connects lower levels to accelerated biological aging. No klotho-based therapy is FDA-approved, and human clinical evidence for anti-aging effects remains early, but the science is developing fast enough that anyone interested in longevity tracking should understand what klotho is, what the evidence actually says, and which biomarkers sit in the same biological neighborhood.
What Is Klotho, Exactly?
Alpha-klotho (encoded by the KL gene) is a transmembrane protein produced primarily in the kidney tubules but also in the brain, pancreas, and other tissues. It exists in two functional forms:
The distinction matters because s-klotho is the form researchers measure in blood when tracking klotho as a potential biomarker. It is also the form most relevant to systemic effects on the cardiovascular system, brain, and immune function.
The Aging Connection: Klotho Declines Over Time
A comprehensive 2022 review published in Ageing Research Reviews (Abraham et al.) analyzed dozens of published studies and confirmed a consistent pattern: mean blood klotho levels in healthy individuals decrease with age. The decline is steeper in people with kidney disease, metabolic conditions, and neurodegenerative disorders.
Functionally, mice engineered to lack klotho develop a rapid-aging syndrome that includes vascular calcification, muscle wasting, cognitive impairment, and shortened lifespan. The reverse experiment, genetically overexpressing klotho, extends mouse lifespan by 20 to 30 percent and produces cardiovascular and metabolic protection.
This clean cause-and-effect relationship in rodents is what generated excitement about klotho as a longevity target. The challenge, as with most longevity biology, is that animal results do not automatically translate to humans, and no completed human randomized controlled trial has tested klotho supplementation for anti-aging effects.
The FGF23 Axis: Why the Kidneys Matter
Understanding klotho means understanding FGF23. Fibroblast growth factor 23 is a hormone produced by bone cells. Its primary job is to signal the kidneys to excrete phosphate and regulate vitamin D metabolism. To do that job, FGF23 needs membrane-bound klotho as a co-receptor on kidney tubule cells.
When klotho levels drop (as they do with age and kidney disease), FGF23 signaling becomes dysregulated. Phosphate accumulates in the blood, vitamin D metabolism shifts, and calcification of blood vessels accelerates. This is one reason researchers see a strong association between low klotho, declining kidney function, and cardiovascular risk.
A 2024 study identified that serum alpha-klotho levels below approximately 700 pg/mL are associated with elevated all-cause mortality risk, with a threshold near 548 pg/mL predicting cardiovascular mortality specifically. These are observational findings, not intervention targets, but they illustrate why tracking kidney function markers alongside klotho biology makes scientific sense.
Klotho and the Brain: The 2023 Nature Aging Landmark Study
The most widely discussed recent klotho finding comes from Castner et al. (2023, Nature Aging). The research team administered a single subcutaneous injection of low-dose rhesus klotho protein, 10 micrograms per kilogram body weight, to aged rhesus macaques averaging roughly 22 years old (a putative human equivalent of about 65 years). Within four hours, treated animals showed measurable improvements in working memory performance. At two weeks, cognitive benefits remained detectable.
Key details that matter for interpreting this study:
The authors concluded that systemic low-dose klotho treatment "may prove therapeutic in aging humans." That language is appropriately cautious. The study is a significant scientific step, but it is one data point in an early-stage research program, not a clinical recommendation.
The KL-VS Genetic Variant: Longevity Written in DNA
Beyond circulating protein levels, genetics add another layer. The KL-VS variant is a functional haplotype in the KL gene that changes two amino acids in the klotho protein and appears to affect how it is secreted. Observational data in humans associate heterozygous KL-VS carriers (one copy of the variant) with longer lifespan in some population cohorts, better cognitive performance in midlife, and reduced Alzheimer's disease risk in certain genetic backgrounds. Homozygous KL-VS carriers (two copies) appear to lose these advantages. The biology is not fully resolved, but the KL-VS data provide human genetic evidence that variation in the klotho system meaningfully influences aging trajectories.
What Researchers Are Studying Now: Gene Therapy and Protein Administration
Because klotho is a protein (not a small molecule), conventional oral supplementation faces significant biological barriers. The field is currently exploring delivery approaches:
|---|---|---|
None of these approaches has completed a Phase 3 human trial. Klotho is not FDA-approved for any indication. Any clinic or product claiming to sell "klotho therapy" outside a registered clinical trial is operating outside the current evidence base. Always discuss research participation or emerging therapies with a licensed healthcare provider.
One area with the most accessible, consistent human data is aerobic exercise. Multiple observational studies show that higher physical activity levels associate with higher circulating klotho, though the effect sizes are modest and the research does not establish that exercise is raising klotho specifically.
What to Track: Longevity Biomarkers in the Klotho Neighborhood
Klotho does not operate in isolation. It sits at the intersection of kidney function, phosphate and mineral metabolism, inflammation, and the IGF-1 signaling axis. If you are working with a healthcare provider to monitor your biological aging, these are the biomarkers most commonly discussed alongside klotho research:
|---|---|
Tracking a panel like this over months and years gives you longitudinal data on the systems klotho is thought to regulate, even before klotho itself is a routine clinical measurement. A single result tells you little; a trend over time tells you something meaningful. You can start logging these markers in your [MyProtocolStack dashboard](/auth/login?mode=signup) and bring that data to your provider visits.
How Klotho Relates to Peptide Research
Klotho is sometimes discussed alongside peptide protocols in longevity circles, but it is important to be precise: klotho is a full-length protein (over 1,000 amino acids), not a peptide drug. Comparing it to research peptides like [epithalon](/peptides/epithalon), [MOTS-c](/peptides/mots-c), or [tesamorelin](/peptides/tesamorelin) is scientifically inaccurate. Those compounds are short amino acid chains with distinct mechanisms, regulatory histories, and evidence bases.
What they share is conceptual territory: researchers are studying whether these molecules can influence biological aging pathways. Klotho is arguably the most upstream and pleiotropic of the group, touching kidney function, the cardiovascular system, brain synaptic plasticity, and mineral metabolism simultaneously. That breadth is what makes it scientifically interesting and also what makes translation to human therapy complex.
Frequently Asked Questions
What is klotho and why do researchers call it a longevity protein?
Klotho is a protein produced primarily in the kidneys that circulates in the bloodstream. It was first identified in 1997 when mice lacking the gene developed a syndrome resembling premature aging, while animals with elevated klotho expression lived longer. These observations prompted researchers to study whether klotho plays a similar protective role in aging humans.
Does klotho decline as you get older?
Yes. Observational data consistently show that circulating alpha-klotho in blood decreases with age in healthy adults and declines further in people with chronic kidney disease, metabolic conditions, and neurodegenerative diseases. No intervention is currently approved to restore or maintain klotho levels in humans.
What did the 2023 Nature Aging monkey study actually show?
Castner et al. (2023) administered a single low-dose injection of rhesus klotho protein to aged rhesus macaques averaging about 22 years old. Animals showed improved working memory within four hours, with benefits still measurable two weeks later. This is preclinical (nonhuman primate) research. No equivalent human clinical trial has been completed.
Is klotho a peptide drug I can take?
No. Klotho is a large protein, not a peptide drug, and it is not FDA-approved for any use. Research approaches include recombinant protein and gene therapy, all in early Phase 1 stages. There are no approved klotho supplements or drugs for human anti-aging use as of 2026. Always consult your licensed healthcare provider.
What biomarkers should I track alongside klotho biology?
Researchers commonly measure kidney function (eGFR, creatinine), serum phosphate, FGF23, hs-CRP, IGF-1, vitamin D (25-OH), ApoB, and blood pressure. Tracking these over time gives you a longitudinal window into the biological systems klotho is thought to regulate. Explore the full [biomarkers hub](/biomarkers) to see which markers you can log today.
Sources
1. Castner SA, et al. "Longevity factor klotho enhances cognition in aged nonhuman primates." Nature Aging, 2023.
2. Abraham CR, Li A. "Aging-suppressor klotho: Prospects in diagnostics and therapeutics." Ageing Research Reviews, 2022.
3. Prud'homme GJ, et al. "Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations." Frontiers in Aging, 2022.
4. Kuro-o M, et al. "Mutation of the mouse klotho gene leads to a syndrome resembling ageing." Nature, 1997.
5. "Associations Between Serum Soluble alpha-Klotho and the Prevalence of Specific Cardiovascular Disease." 2022.
6. Longevity Technology. "Klothea initiates longevity-focused human trial of klotho therapy." 2024.
7. "Anti-Inflammatory Role of the Klotho Protein and Relevance to Aging." 2024.
8. ClinicalTrials.gov. "Klotho Gene Therapy (Phase 1, healthy adults)." 2025-2026.
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment. The information in this article is for educational purposes only. Always consult a qualified healthcare professional before making any changes to your health protocols, pursuing experimental therapies, or interpreting lab results.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →